Board of Directors

Chairman of 2cureX AB and 2cureX A/S

Tonni Bülow-Nielsen has extensive medical device and life science experience as Partner (until 2020 he was also Managing Partner and Senior Vice President in the executive leadership group) through more than 16 years in EIFO (Export and Investment Fund of Denmark), previously Vækstfonden. Today Tonni is a Partner in the Medtech and Lifescience team in EIFO for venture investments and manage a significant portfolio of investments through Board positions, value creation and transactions. Before joining Vækstfonden in 2007, Tonni was founder and CEO of DanMed A/S and Nordic Medical Group A/S from 2002-2007.

Tonni lived and worked in USA 1996-2002 as SVP for USA and President of ELA Medical (Canada & South America), a part of the Sanofi Group, Global Marketing Director for St. Jude Medical (Los Angeles, USA, and Japan). Before this he was Business Unit Director for St. Jude Medical EEMEA (Brussels, Belgium), Country Manager for Guidant Nordic Area and Sales Manager for Danica Biomedical.

His educational background is medical engineering, and he holds an executive MBA from the Scandinavian International Management Institute.

Tonni has been the chairman of 2cureX AB since 2023 and 2cureX A/S since 2023.

Other board assignments

Evosep, Reapplix, TeesuVac, Microshade, Cathvision, Arcedi Biotech and ILS Denmark.

Independence

Independent of management, the company and major shareholders.

Vice-Chairman, CEO and Founder of 2cureX AB and 2cureX A/S

Ole Thastrup (B. 1953) is co-founder of 2cureX. He has been a board member of 2cureX since its inception.

Ole holds a MSc in Pharmacy and a PhD in Pharmacology and Medicinal Chemistry. Ole is also a Professor at the University of Copenhagen. Prior to 2cureX Ole was Head of Carlsberg Biosector where he was responsible for Carlsberg’s biomedical research. Before that, Ole was the scientific founder and Chief Scientific Officer of BioImage A/S (now Thermo Fisher BioImage) which was spun out from Novo Nordisk A/S. Ole is the inventor in several families of globally issued patents. He had advised several venture funds and is a member of granting institutions (e.g. Novo Nordisk Foundation).

2cureX share ownership and warrants
4 156 134 shares via own company

Other board assignments
OT311 APS

Independence
Affiliated to management, the company, and major shareholders

Board member and Founder of 2cureX AB and 2cureX A/S

Grith holds a degree of Biomedical Laboratory Science.

Grith has comprehensive experience in developing and running drug screening campaigns. Grith is the inventor of several patents on advanced cell-based, high throughput screening technologies. She is a co-founder of BioImage A/S, spun out of Novo Nordisk and now part of the imaging division of Thermo Fisher Scientific. She was responsible for the development of functional cell-based assays, and for their transfer to partners such as Amersham plc (now GE Healthcare).

2cureX share ownership and warrants
681 708 shares

Board member of 2cureX A/S

Patrick Aisher is a serial entrepreneur who has invested in the life sciences industry since 1997. As Chairman of Kinled, he has focused on biomedical technology companies developing medical devices, biopharmaceuticals, and healthcare services, making over 60 direct investments in the sector.

Patrick has a broad portfolio, including various successful NASDAQ exits, two trade sale exits at $40M (KB Medical to Globus in 2018) and $150M+ (Medina Medical to Medtronic in 2016), and two exits via international licensing transactions valued at $350M+. He is a partner in a $200M venture fund for private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. Over the years, Patrick has cultivated strong relationships with key industry players, positioning himself as a significant figure in the venture capital landscape.

Patrick is a Director of Aleva Neurotherapeutics SA and PreComb Therapeutics AG, in Switzerland, and has identified and invested in early-stage spin-off opportunities from universities in Barcelona, Zurich, Oxford, Boston, Stanford, Northeastern, Texas, NYU, Lausanne, and Geneva. His commitment to fostering innovation in the life sciences sector is reflected in his active involvement in mentoring and supporting emerging entrepreneurs, as well as his participation in various industry conferences and panels.